- Home
- NXTC vs IMRN Comparison
NXTC vs IMRN Comparison
Compare NXTC & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- IMRN
- Stock Information
- Founded
- NXTC 2015
- IMRN 1994
- Country
- NXTC United States
- IMRN Australia
- Employees
- NXTC N/A
- IMRN N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- IMRN Health Care
- Exchange
- NXTC Nasdaq
- IMRN Nasdaq
- Market Cap
- NXTC 13.9M
- IMRN 9.2M
- IPO Year
- NXTC 2019
- IMRN N/A
- Fundamental
- Price
- NXTC $0.49
- IMRN $1.77
- Analyst Decision
- NXTC Strong Buy
- IMRN Strong Buy
- Analyst Count
- NXTC 2
- IMRN 1
- Target Price
- NXTC $3.50
- IMRN $5.00
- AVG Volume (30 Days)
- NXTC 141.9K
- IMRN 49.4K
- Earning Date
- NXTC 05-01-2025
- IMRN 06-10-2025
- Dividend Yield
- NXTC N/A
- IMRN N/A
- EPS Growth
- NXTC N/A
- IMRN N/A
- EPS
- NXTC N/A
- IMRN N/A
- Revenue
- NXTC N/A
- IMRN $4,048,286.00
- Revenue This Year
- NXTC N/A
- IMRN N/A
- Revenue Next Year
- NXTC N/A
- IMRN N/A
- P/E Ratio
- NXTC N/A
- IMRN N/A
- Revenue Growth
- NXTC N/A
- IMRN 82.90
- 52 Week Low
- NXTC $0.22
- IMRN $1.50
- 52 Week High
- NXTC $1.82
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- NXTC 55.20
- IMRN 47.77
- Support Level
- NXTC $0.45
- IMRN $1.75
- Resistance Level
- NXTC $0.52
- IMRN $1.92
- Average True Range (ATR)
- NXTC 0.05
- IMRN 0.19
- MACD
- NXTC 0.01
- IMRN 0.00
- Stochastic Oscillator
- NXTC 66.47
- IMRN 43.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.